Last edition
News about "Akums Drugs and Pharmaceuticals "
Akums Launches DCGI-Approved Triple-Action Therapy for Diabetic Neuropathic Pain
Akums Drugs & Pharmaceuticals has introduced a DCGI-approved triple-action capsule that combines pregabalin, methylcobalamin and delayed-release duloxetine to offer comprehensive management of diabetic peripheral neuropathic pain while supporting nerve regeneration.
Akums Drugs And Pharmaceuticals | 01/07/2026 | By News Bureau | 110
Akums Secures European CEP Approval for Cefpodoxime Proxetil API
Akums Drugs and Pharmaceuticals has received a Certificate of Suitability from the EDQM for its Cefpodoxime Proxetil API, reinforcing the company’s commitment to global quality compliance and enhancing its position as a trusted manufacturing partner for regulated international markets.
Akums Drugs And Pharmaceuticals | 06/06/2026 | By News Bureau
Akums Drugs and Pharmaceuticals introduces DCGI-approved Lasmiditan dispersible tablets, offering faster, patient-friendly migraine relief with improved compliance, especially for patients facing nausea and difficulty swallowing during acute attacks.
Akums Drugs And Pharmaceuticals | 18/03/2026 | By News Bureau | 140
Akums to Set Up Manufacturing Facility in Zambia
Akums Drugs and Pharmaceuticals has signed a framework agreement with the Government of the Republic of Zambia to establish a local manufacturing facility in the country and supply essential medicines.
Akums Drugs And Pharmaceuticals | 25/08/2025 | By Dineshwori | 360
Akums Expands Analgesic Portfolio with New High-Concentration Paracetamol Oral Suspension
Akums Drugs and Pharmaceuticals has introduced Paracetamol Oral Suspension 500mg/5ml in the Indian market, strengthening its position in pain and fever management and adding a significant product to the analgesic and antipyretic category.
Akums Drugs And Pharmaceuticals | 22/07/2025 | By Dineshwori | 453
Akums Combines Two Potent Diabetes Medicines for Enhanced Treatment Efficacy
Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, aids in eliminating excess glucose via urine while delivering additional benefits such as improved cardiovascular and renal outcomes, along with better weight management.
Akums Drugs And Pharmaceuticals | 03/02/2025 | By Aishwarya | 692
Akums Signs INR 1,760 Crore CDMO Deal with a Global Pharma Company
Akums group will manufacture and supply multiple SKUs of oral liquid formulation to be marketed in multiple European countries by the company.
Akums Drugs And Pharmaceuticals | 26/12/2024 | By Aishwarya | 531
Akums Drugs Appoints Amrut Medhekar as New CDMO CEO
Akums Drugs and Pharmaceuticals Ltd. has announced the appointment of Amrut Medhekar as Chief Executive Officer of its CDMO business, approved by the company’s Board of Directors in a recent meeting.
Akums Drugs And Pharmaceuticals | 02/09/2024 | By Aishwarya | 810
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy